FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

Female GH Optimization

GH Optimizationintermediate

85

sintesi

85
Share
Peptidi

2

Media giornaliera mcg

2,200

Livello

intermediate

Aggiunto

May 17, 2026

Panoramica

The Female GH Optimization stack pairs Ipamorelin with Tesamorelin specifically because these two peptides offer the most favorable side-effect profile for women seeking growth hormone benefits without androgenic or metabolic complications. Tesamorelin is a 44-amino-acid GHRH analog that is the only peptide in this category with full FDA approval (marketed as Egrifta for HIV-associated lipodystrophy). It stimulates pituitary GH production through the GHRH receptor, producing physiological GH pulses that closely mimic natural secretion patterns. Women naturally produce more GH than men (approximately 2x the daily output) but experience a sharper decline with age, making GH optimization particularly impactful for female physiology. Tesamorelin has been shown in clinical trials to reduce visceral adipose tissue by 15-20% without affecting subcutaneous fat — making it uniquely suited for the central adiposity pattern common in perimenopause and menopause. Its effects on IGF-1 are modest and predictable, staying within physiological ranges. Ipamorelin complements Tesamorelin by adding ghrelin-pathway stimulation without the appetite increase, cortisol elevation, or prolactin changes seen with other GH secretagogues. For women, the absence of prolactin effects is particularly important as elevated prolactin can disrupt menstrual cycles and breast tissue. The combination produces amplified GH pulses (via GHRH + GHS synergy) while maintaining clean hormonal profiles. Benefits typically observed include improved skin elasticity and thickness, reduced visceral fat, better sleep architecture, improved bone mineral density markers, and enhanced recovery from exercise. This stack is well-suited for women over 35 seeking comprehensive anti-aging and body composition benefits.

Protocollo di Dosaggio

Ipamorelin

Every day· subcutaneous

Leggi di più su Ipamorelin →

200 mcg

per dose

Tesamorelin

Every day· subcutaneous

Leggi di più su Tesamorelin →

2,000 mcg

per dose

Obiettivi & Evidenze

Growth hormoneBody compositionSkin qualitySleepBone density
Livello di Evidenza:RCT umano

Avvertenze

  • Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy. Off-label use for anti-aging is common but not approved. Ipamorelin remains FDA Category 2 (restricted) as of July 2026.

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.